Acura Pharmaceuticals - 15 Year Stock Price History | ACUR
Historical daily share price chart and data for Acura Pharmaceuticals since 2011 adjusted for splits and dividends. The latest closing stock price for Acura Pharmaceuticals as of June 19, 2026 is 0.00.
- The all-time high Acura Pharmaceuticals stock closing price was 26.25 on October 20, 2011.
- The Acura Pharmaceuticals 52-week high stock price is 0.01, which is % above the current share price.
- The Acura Pharmaceuticals 52-week low stock price is 0.00, which is % below the current share price.
- The average Acura Pharmaceuticals stock price for the last 52 weeks is 0.00.
| Acura Pharmaceuticals Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 0.0014 | 0.0005 | 0.0100 | 0.0001 | 0.0004 | -20.00% |
| 2025 | 0.0055 | 0.0002 | 0.0200 | 0.0001 | 0.0005 | 150.00% |
| 2024 | 0.0072 | 0.0010 | 0.0275 | 0.0002 | 0.0002 | 100.00% |
| 2023 | 0.0184 | 0.0500 | 0.0500 | 0.0000 | 0.0001 | -99.80% |
| 2022 | 0.3661 | 0.5300 | 0.5575 | 0.0012 | 0.0500 | -90.00% |
| 2021 | 0.4635 | 0.2100 | 0.7486 | 0.1830 | 0.5000 | 138.10% |
| 2020 | 0.2839 | 0.2800 | 0.4300 | 0.1360 | 0.2100 | -8.70% |
| 2019 | 0.2503 | 0.1395 | 0.4500 | 0.1200 | 0.2300 | 100.17% |
| 2018 | 0.3613 | 0.3600 | 0.8400 | 0.0733 | 0.1149 | -71.55% |
| 2017 | 0.5162 | 0.8400 | 1.3000 | 0.3210 | 0.4039 | -47.31% |
| 2016 | 1.8810 | 2.2700 | 3.4400 | 0.7400 | 0.7665 | -69.34% |
| 2015 | 3.2919 | 2.5000 | 5.1500 | 1.6900 | 2.5000 | 11.11% |
| 2014 | 5.5121 | 8.4000 | 10.1500 | 2.1500 | 2.2500 | -73.05% |
| 2013 | 9.8972 | 11.6000 | 15.2000 | 7.0000 | 8.3500 | -24.77% |
| 2012 | 12.9750 | 17.4000 | 20.7000 | 5.5000 | 11.1000 | -36.39% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $37.024B | 11.42 |
| BridgeBio Pharma (BBIO) | United States | $13.499B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.610B | 22.80 |
| Aspen Pharmacare (APNHY) | South Africa | $4.116B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.582B | 18.23 |
| Taysha Gene Therapies (TSHA) | United States | $1.876B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $1.747B | 1.19 |
| Personalis (PSNL) | United States | $1.065B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.808B | 7.48 |
| Assembly Biosciences (ASMB) | United States | $0.400B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.207B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.045B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |